Literature DB >> 12504341

Identification of an abnormal beryllium lymphocyte proliferation test.

Edward L Frome1, Lee S Newman, Donna L Cragle, Shirley P Colyer, Paul F Wambach.   

Abstract

The potential hazards from exposure to beryllium or beryllium compounds in the workplace were first reported in the 1930s. The tritiated thymidine beryllium lymphocyte proliferation test (BeLPT) is an in vitro blood test that is widely used to screen beryllium exposed workers in the nuclear industry for sensitivity to beryllium. The clinical significance of the BeLPT was described and a standard protocol was developed in the late 1980s. Cell proliferation is measured by the incorporation of tritiated thymidine into dividing cells on two culture dates and using three concentrations of beryllium sulfate. Results are expressed as a 'stimulation index' (SI) which is the ratio of the amount of tritiated thymidine (measured by beta counts) in the simulated cells divided by the counts for the unstimulated cells on the same culture day. Several statistical methods for use in the routine analysis of the BeLPT were proposed in the early 1990s. The least absolute values (LAV) method was recommended for routine analysis of the BeLPT. This report further evaluates the LAV method using new data, and proposes a new method for identification of an abnormal or borderline test. This new statistical-biological positive (SBP) method reflects the clinical judgment that: (i) at least two SIs show a 'positive' response to beryllium; and (ii) that the maximum of the six SIs must exceed a cut-point that is determined from a reference data set of normal individuals whose blood has been tested by the same method in the same serum. The new data is from the Y-12 National Security Complex in Oak Ridge (Y-12) and consists of 1080 workers and 33 non-exposed control BeLPTs (all tested in the same serum). Graphical results are presented to explain the statistical method, and the new SBP method is applied to the Y-12 group. The true positive rate and specificity of the new method were estimated to be 86% and 97%, respectively. An electronic notebook that is accessible via the Internet was used in this work and contains background information and details not included in the paper.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504341     DOI: 10.1016/s0300-483x(02)00439-0

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  7 in total

1.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

Review 2.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 3.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

4.  Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

Authors:  Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

5.  Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers.

Authors:  Kristin J Cummings; David C Deubner; Gregory A Day; Paul K Henneberger; Margaret M Kitt; Michael S Kent; Kathleen Kreiss; Christine R Schuler
Journal:  Occup Environ Med       Date:  2006-10-16       Impact factor: 4.402

6.  Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility.

Authors:  Carrie A Thomas; Rachel L Bailey; Michael S Kent; David C Deubner; Kathleen Kreiss; Christine R Schuler
Journal:  Public Health Rep       Date:  2009 Jul-Aug       Impact factor: 2.792

7.  Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells.

Authors:  Blessing Mukonoweshuro; Christopher Jf Brown; John Fisher; Eileen Ingham
Journal:  J Tissue Eng       Date:  2014-04-29       Impact factor: 7.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.